Amneal said late Thursday that it was the second straight year the company was recognized by Generics Bulletin, a global newsletter for the generic drug and biosimilars industries.
In terms of prescriptions, Amneal is now the seventh-largest U.S. manufacturer of generic pharmaceuticals, and it’s the fastest-growing company among the top 10 generics manufacturers, the drug maker reported.
With annual U.S. sales reaching $1 billion, Amneal’s portfolio has around 86 Food and Drug Administration-approved molecules, another 171 are in development and 107 are pending approval. The product pipeline encompasses offerings across multiple therapeutic areas and virtually all dosage forms, noted the privately held company, which has its U.S. headquarters in Bridgewater, N.J., and global headquarters in Zug, Switzerland..
“Amneal prides itself in staying true to its core values: integrity, accountability, hard work, and collaboration,” stated Chirag Patel, co-chief executive officer and chairman of Amneal. “Winning this award is proof that acting on our values and executing our growth strategy has enabled us to continue to deliver on our promise of providing high-quality, affordable medicines for patients around the world.”